3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
51
Rectal Neoplasms
27
Colonic Neoplasms
16
Stomach Neoplasms
14
Carcinoma, Hepatocellular
14
Neoplasm Metastasis
9
Adenocarcinoma Of Esophagus
7
Esophageal Neoplasms
6
Neoplasms
5
Cholangiocarcinoma
5
Recurrence
3
Pancreatic Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Digestive System Neoplasms
3
Adenocarcinoma
3
Ovarian Neoplasms
2
Liver Neoplasms
2
Intestinal Neoplasms
2
Gastrointestinal Neoplasms
2
Gastrointestinal Diseases
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Biliary Tract Neoplasms
2
Peritoneal Neoplasms
1
Pancreatic Adenocarcinoma
1
Operable T2-3N+M0 Rectal Cancer (Stage III)
1
Neurotoxicity Syndromes
1
Metastatic Colorectal Adenocarcinoma
1
Locally Advanced Pancreatic Carcinoma(LAPC)
1
Locally Advanced Colorectal Carcinoma
1
Intestinal Diseases
1
Interventions
Gemcitabine
26
Capecitabine
16
Oxaliplatin
14
Fluorouracil
13
Cisplatin
12
Leucovorin
9
pembrolizumab
5
Erlotinib Hydrochloride
5
Bevacizumab
5
durvalumab
4
Trastuzumab
4
Specimen Handling
4
Sorafenib
4
Magnetic Resonance Spectroscopy
4
130-nm albumin-bound paclitaxel
4
trifluridine tipiracil drug combination
3
Lapatinib
3
Irinotecan
3
Carboplatin
3
Biopsy
3
tremelimumab
2
toripalimab
2
regorafenib
2
lenvatinib
2
dehydroftorafur
2
cobimetinib
2
atezolizumab
2
anlotinib
2
Nivolumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gallbladder Neoplasms
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts